Tratamiento habitual con formoterol para el asma crónica: eventos adversos graves
Información
- DOI:
- https://doi.org/10.1002/14651858.CD006923.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 18 abril 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Vías respiratorias
- Copyright:
-
- Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
CJC: conception of the idea, study selection and data collection, statistical analysis and co‐writing of the review.
MJC: background information (including Appendices), study selection and co‐writing of the review.
Sources of support
Internal sources
-
St George's University of London, UK.
External sources
-
NIHR, UK.
Programme grant
Declarations of interest
None known.
Acknowledgements
We thank Susan Hansen and Elizabeth Stovold of the Cochrane Airways Group for their assistance in searching for trials and obtaining the abstracts and full reports, and extraction of data on trial characteristics, Toby Lasserson for assistance in checking outcome data and Anne Tattersfield for helpful comments. We are grateful to Martin Shaw (Novartis) for providing data in relation to FitzGerald 1999, Onno van Schayck for providing data for van Schayck 2002, Vincent Le Gros (Novartis) for providing data in relation to Molimard 2001, Andrea von Berg for providing data in relation to Von Berg 2003 and Robyn Von Maltzahn (AstraZeneca) for providing data in relation to Ekstrom 1998; Ekstrom 1998a; van der Molen 1997; Zimmerman 2004.
CRG Funding Acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Airways Group.
Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2012 Apr 18 | Regular treatment with formoterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Matthew J Cates | |
| 2008 Oct 08 | Regular treatment with formoterol for chronic asthma: serious adverse events | Review | Christopher J Cates, Matthew J Cates, Toby J Lasserson | |
| 2008 Jan 23 | Regular treatment with formoterol for chronic asthma: serious adverse events | Protocol | Christopher J Cates, Matthew J Cates, Toby J Lasserson | |
Differences between protocol and review
We did not use risk difference as the primary metric for analysis of rare events, due to new advice in the latest revision of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). One of the peer reviewers also pointed out that Bradburn 2007 cautions against the use of inverse‐variance and DerSimonian and Laird methods for sparse data, so for the 2009 update we used the Peto OR for the primary analysis, as no continuity correction is required for zero cells. This brings the analysis for this review in line with the other reviews in this series.
Also we investigated reporting bias by comparing published and unpublished serious adverse events, and investigating the impact of using drug‐related adverse events and the combined results from serious and non‐serious adverse events.
